Pralex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pralex

What is Pralex? Identity and Classification

Property Description
Active ingredient Escitalopram (typically as oxalate salt)
Form Film-coated tablets, oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General Purpose Modulating neurochemical equilibrium for mental health support
Origin Synthetic compound

What Type of Medicine is Pralex? Defining the SSRI Class

Pralex is a synthetic, prescription-only medication that is clinically recognized as an antidepressant and belongs specifically to the Selective Serotonin Reuptake Inhibitor (SSRI) class of psychotropic agents. The primary objective of this class is to modulate serotonergic neurotransmission within the central nervous system, helping to stabilize brain chemistry.

The active substance, Escitalopram, is the single-component product and is chemically defined as the pure S-enantiomer of its precursor compound, Citalopram. This high degree of stereochemical purity is a differentiating factor, as the S-enantiomer exhibits focused selectivity for the serotonin transporter. This high selectivity is key to the drug's mechanism.

Escitalopram: Composition, Origin, and Unique Form

The active compound in Pralex is Escitalopram, a synthetic compound derived from a bicyclic phthalane structure, often formulated as the salt Escitalopram oxalate. Its unique, pure enantiomer status ensures focused pharmacological activity.

For oral administration, Pralex is primarily supplied in two standard dosage forms: film-coated tablets and a liquid oral solution. The tablets and solution contain the active Escitalopram base alongside pharmaceutical excipients. This choice of a pure enantiomer is designed to maximize therapeutic efficacy by concentrating activity on the intended biochemical target.

General Purpose: What Does Pralex Primarily Help To Do?

The general therapeutic purpose of Escitalopram is to support neurochemical equilibrium by selectively increasing the availability of active serotonin at the nerve synapses. By sustaining more effective signaling between nerve cells, the medication’s intended benefit is to provide foundational relief and emotional stability.

This action is considered a fundamental mechanism for aiding patients with mood disorders and anxiety disorders. Clinically, the use of Escitalopram is associated with helping to restore balance to the intrinsic system responsible for the regulation of emotions and behavioral responses.

Regulatory References

  1. NIH Drug Information

What side effects are possible with Pralex?

Possible Side Effects and Safety Information

Official regulatory documents classify the documented effects of Pralex (Escitalopram) by frequency and affected body system.

Frequency-Classified Adverse Reactions

The following non-serious effects are officially recognized and categorized by their reported incidence:

Classification Examples of Documented Effects
Very Common (ge 10%) Nausea, Headache
Common (1-10%) Insomnia, Somnolence, Diarrhea, Dry mouth, Increased sweating, Fatigue, Ejaculation disorder, Decreased libido

Adverse effects are generally most frequent during the first one to two weeks of treatment and typically lessen in intensity and frequency with continued therapy. Abrupt discontinuation is associated with the emergence of withdrawal symptoms (Discontinuation Syndrome).


Serious and Clinically Significant Adverse Reactions

The official labeling documents rare but serious risks that require heightened attention:

  • Suicidal Thoughts and Behaviors: A Boxed Warning exists concerning an increased risk of suicidal ideation and behavior in adolescents and young adults (le 24 years) during the initial phase of treatment or following dose adjustments.
  • Serotonin Syndrome: A rare, potentially life-threatening reaction associated with the accumulation of serotonin, particularly when used with other serotonergic agents (e.g., MAOIs, Triptans).
  • Cardiac Events: Reports include QT interval prolongation and the risk of a severe heart rhythm abnormality known as Torsade de pointes (TdP), particularly in patients with pre-existing heart conditions or electrolyte imbalances.
  • Hyponatremia: The risk of low sodium levels in the blood is documented, often observed more frequently in the older adult population.
  • Abnormal Bleeding: An increased risk of bleeding events (e.g., gastrointestinal hemorrhage, easy bruising) is documented, especially with concomitant use of medications that affect blood clotting.

Safety Restrictions and Considerations

Contraindications include use with Monoamine Oxidase Inhibitors (MAOIs) and Pimozide due to the high risk of Serotonin Syndrome and QTc prolongation, respectively. Caution is advised for patients with a history of seizures or untreated narrow-angle glaucoma. Due to slower clearance, dosage may be restricted for older adults and patients with hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Pralex (Escitalopram) requires immediate medical attention, as mandated by regulatory authorities. The officially documented overdose manifestations involve several physiological systems. Central Nervous System effects can include Somnolence, Agitation, Tremor, Delirium, Convulsions, and Coma. Cardiovascular signs documented in overdose reports are Tachycardia, Hypotension, Arrhythmias, and clinically relevant QT prolongation, which carries a risk of Torsades de pointes.

A primary concern in overdose is the development of Serotonin Syndrome, a potentially life-threatening complication noted in regulatory documents. Overdose severity, including fatal outcomes, is most often associated with the concomitant ingestion of other substances.

The regulator-mandated course of action is to seek immediate medical attention and contact emergency services or a Poison Control Center for any suspected exposure above the prescribed dose. Since no specific antidote is known for Escitalopram overdose, treatment in a healthcare setting is strictly supportive and symptomatic. Continuous monitoring of cardiac and vital signs is required, with specific requirements for ECG monitoring in patients presenting with altered metabolism or co-ingestion of other drugs that affect the heart's rhythm.

Therapeutic Uses of Pralex

What Pralex Treats: Main Uses and Benefits

Pralex is commonly used across therapeutic areas involving heightened emotional or psychological tension. This medication is applied to help manage Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Panic Disorder, and Social Anxiety Disorder.

The primary therapeutic focus is on addressing symptom clusters that may interfere with daily functioning, such as persistent low mood, excessive worry, and the recurrence of panic attacks. The medication may assist with maintaining functional stability and emotional balance, providing support that helps patients cope more steadily with symptom fluctuations.

It is relevant for easing symptoms that become temporarily overwhelming, commonly used during phases of increased distress.

“It supports general well-being by helping to manage the mental burden and contributes to easing the overall symptom load.”

Pralex is considered relevant in Obsessive-Compulsive Disorder (OCD) for managing distressing intrusive thoughts and compulsive rituals.


Quick Fact: Relief for Mental Burden Pralex helps address symptom clusters that may become intense or disruptive, providing supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Pralex? Official Regulatory Eligibility

The eligibility for using Pralex (Escitalopram) is defined strictly by government regulatory documents, which establish specific populations that are approved, restricted, or prohibited from using the medicine. The primary established population is Adults (ages 18 and older). Use in Adolescents (ages 12–17) is established, but is restricted to Major Depressive Disorder (MDD); use is not established for children under 12.


Contraindications (Absolute Non-Eligibility)

Pralex is absolutely contraindicated for patients who have known hypersensitivity to escitalopram or citalopram. It must not be used concurrently with Non-selective Monoamine Oxidase Inhibitors (MAOIs), Pimozide, or in patients diagnosed with congenital Long QT syndrome or other QT interval prolongation conditions.


Conditional Use and Restrictions

Older adults (ages 65 and over) are an eligible population but are subject to a lower maximum recommended dose, defining a population restriction. Conditional use and caution are required for individuals with severe hepatic impairment, severe renal impairment, a history of seizures, bleeding disorders, or angle-closure glaucoma, as stated in the official labeling. Use during pregnancy and lactation is classified as conditional use, permissible only if the potential benefit justifies the potential risk, as determined by regulatory assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of escitalopram (Pralex) is governed by two principal regulatory concerns: additive pharmacodynamic effects and altered pharmacokinetic clearance.

Formally Contraindicated Combinations

Certain combinations of medicines are explicitly prohibited by regulatory authorities due to the documented risk of severe adverse outcomes:

  • Monoamine Oxidase Inhibitors (MAOIs): Co-administration is contraindicated due to the high risk of Serotonin Syndrome. A mandatory 14-day separation period is required when switching between escitalopram and an irreversible MAOI, as specified in regulatory labeling.
  • Pimozide: Concomitant use is contraindicated due to the official documentation of a risk for QT-interval prolongation (a cardiac conduction effect).

Documented Pharmacodynamic and Metabolic Interactions

Interaction Type Interacting Substances / Categories Regulatory Description
Serotonergic Reinforcement Triptans, Fentanyl, Lithium, Tramadol, St. John's Wort Increased potential for Serotonin Syndrome (additive effect on serotonin levels).
Bleeding Risk NSAIDs, Aspirin, Warfarin, other Antiplatelet Agents Increased risk of abnormal bleeding (due to effects on platelet aggregation).
Metabolic Inhibition CYP2C19 and CYP3A4 Inhibitors (e.g., Cimetidine, Omeprazole) Leads to an official increase in escitalopram plasma concentration (increased exposure).
Effect on Other Drugs Drugs metabolized by CYP2D6 (e.g., Metoprolol, some Antidepressants) Escitalopram is a modest CYP2D6 inhibitor, resulting in officially increased exposure of co-administered CYP2D6 substrates.
Substance Interaction Alcohol Co-use is not recommended by regulatory bodies due to possible potentiation of effects on cognitive and motor performance.

This interaction structure establishes clear constraints on co-use, focusing specifically on combinations that result in prohibited cardiac risks or potential serotonergic overload, as explicitly defined within government-approved drug labeling.

Mechanism of Action

Selective Serotonin Reuptake and Allosteric Modulation

Pralex (escitalopram) functions as a highly selective serotonin reuptake inhibitor (SSRI) within the central nervous system. Its primary action involves binding to the serotonin transporter (SERT) protein located on presynaptic neurons, thereby blocking the reabsorption of the neurotransmitter serotonin (5-HT) from the synaptic cleft back into the cell. This targeted inhibition results in an increased concentration and prolonged presence of free serotonin in the synaptic space.

In addition to its main binding site, Pralex also engages a distinct allosteric site on the SERT. This secondary binding mechanism stabilizes the conformation of the transporter, increasing the efficiency of the reuptake blockade. This dual interaction modifies early molecular steps, influencing the activity profile of serotonergic pathways, which leads to subsequent molecular and cellular changes throughout the affected neural systems.

Dosage and Administration Information

How Pralex is Used: Official Administration Guidelines

Pralex (Escitalopram) is administered exclusively via the oral route, using either the film-coated tablets or the oral solution. The medication is taken once daily, and the intake can occur in either the morning or the evening, irrespective of meals (with or without food).


Standard Dosing and Schedule

Category Official Protocol Summary
Starting Dose Typically 10 mg once daily for adults.
Maximum Dose 20 mg once daily is the maximum adult recommended dose.
Dose Titration Dose adjustments from 10 mg to 20 mg should occur after a minimum of one week in adults, or a minimum of three weeks for adolescents.

Population-Specific Use and Preparation

The standard regimen is subject to specific limitations for certain populations. The maximum recommended daily dose is 10 mg for older adults (typically aged 65 and above) and for patients diagnosed with hepatic impairment (liver function issues). For patients with mild to moderate renal impairment, no dose adjustment is generally required.

For the oral solution, the prescribed dose must be measured using a calibrated device (such as a dosing syringe or dropper) to ensure accuracy. The liquid may be mixed with a small amount of water, apple juice, or orange juice prior to ingestion. The 10 mg and 20 mg tablets are typically scored to allow for division if a lower dose is needed during titration or discontinuation. The official protocol for cessation involves a gradual dose reduction (tapering) rather than abrupt stopping.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pralex

Evidence for Use in Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)

The research landscape for Escitalopram in both Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) includes short-term Randomized Controlled Trials (RCTs). These studies were designed to compare measured outcomes between the Escitalopram group and a control group, typically an inactive substance (placebo). For MDD, symptom change was measured using scales like the Montgomery-Åsberg Depression Rating Scale (MADRS). For GAD, the Hamilton Anxiety Rating Scale (HAM-A) was commonly used.

Research provides data on changes measured during these short study periods, suggesting patterns in symptom evolution across these conditions. Pooled analysis of some trials indicates that outcomes measured for Escitalopram were generally comparable to those for other common treatments, such as Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), particularly in acute (short-term) treatment.

Long-Term Follow-up and Evidence Gaps

Extended follow-up trials (continuation studies) have explored how symptoms change over time, often lasting six months to one year. Findings from these studies describe patterns in patient-reported experience when treatment was continued, and some trials suggest that continued use was associated with a longer time to recurrence in people who had responded to initial treatment for MDD.

The certainty remains low regarding the full range of potential long-term outcomes, as comparative evidence against every available medication across multiple years is lacking. Data for older adults with multiple pre-existing medical conditions, or for women who are pregnant or breastfeeding, are limited, as these groups are often excluded from initial, large-scale RCTs. Research focusing on specific outcomes reflecting daily functioning or activity level often provides limited data, as many core trials focused mainly on symptom rating scales.

Key Studies & References

  1. NICE Guideline NG222: Depression in adults: treatment and management

Frequently Asked Questions (FAQ)

Common questions about Pralex (FAQ)

Q: How quickly can a person expect to notice any effects from Pralex?

A: Studies and official information indicate that people typically begin to notice initial therapeutic effects, such as improvements in symptoms like mood or anxiety, after approximately two to four weeks of regular treatment. Studies indicate that continued treatment beyond this initial period may be associated with further symptom change.

Q: Are there any side effects of Pralex that typically go away after a while?

A: Regulatory documents state that adverse effects are commonly experienced more frequently and intensely during the first one to two weeks of therapy. Regulatory documents state that these effects typically lessen in intensity and frequency with continued treatment.

Q: What kind of studies have been performed on Pralex?

A: The regulatory approval of Pralex is primarily based on evidence gathered from short-term Randomized Controlled Trials (RCTs). These studies were designed to compare the medicine against an inactive substance (placebo) to evaluate its performance for approved uses.

Q: What information about Pralex is available from the FDA or EMA?

A: Government regulatory bodies like the FDA and EMA provide comprehensive, official product documentation for Pralex. This includes legally mandated details on the medicine’s approved uses, appropriate dosing conditions, detailed safety warnings (such as the Boxed Warning), and summaries of clinical trial data.

Q: What is the evidence regarding Pralex and long-term use?

A: Official documents reference long-term follow-up and continuation studies that have examined patient experiences over periods up to one year. Findings from these studies indicate that continued use was associated with a longer period of time before symptoms recurred in people who had initially responded to treatment.

Q: Can Pralex be used during pregnancy, according to official warnings?

A: Official labeling classifies use during pregnancy as conditional. Regulatory documents state that conditional use is permissible if the potential benefit is assessed to justify the potential risk. Warnings may involve documented reports of specific effects on the newborn or an increased risk of bleeding when the medicine is used late in pregnancy.

Q: Is Pralex suitable for adolescents?

A: Official regulatory documents establish use for adolescents (ages 12–17) but specifically restrict its use to treating Major Depressive Disorder (MDD). Use of Pralex is not established in children under 12 years of age.

Q: Does Pralex need to be taken long-term?

A: The official duration of Pralex treatment is determined by the specific condition being addressed. For many uses, regulatory recommendations include a period of maintenance treatment after an initial response is achieved. The official duration of Pralex use is often assessed periodically.

Q: Can Pralex be taken safely with common pain relievers like ibuprofen?

A: Official documentation notes that co-use of Pralex with non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or aspirin, is known to increase the risk of abnormal bleeding events. This risk is primarily associated with the gastrointestinal system.

Q: Are there certain types of food or drink that should be avoided when taking Pralex?

A: Regulatory bodies officially state that co-use with alcohol is not recommended due to the possible potentiation of effects on cognitive and motor skills. Official product information notes caution regarding grapefruit juice consumption because it can potentially increase the concentration of the medication in the blood.

Q: Is Pralex known to interact with herbal supplements?

A: The herbal supplement St. John's Wort is specifically cited in regulatory documents. Co-use with this supplement is discouraged as it can increase the risk of a severe drug reaction known as Serotonin Syndrome due to additive effects on serotonin levels.

Q: Why is Pralex sometimes not recommended for people with kidney or liver issues?

A: Official documentation states that for patients with hepatic impairment (liver function issues), the drug’s clearance from the body is slower. This decreased clearance can lead to higher concentrations of the medication in the body, which is why the maximum recommended daily dose is restricted for this population.

Q: Can Pralex affect the ability to concentrate?

A: Difficulty concentrating has been reported as a symptom associated with the use of Pralex. The official labeling warns that Pralex may affect judgment, thinking, and motor skills. These effects are why caution is advised when performing tasks that require mental alertness.

Q: Does Pralex have withdrawal effects if stopped abruptly?

A: Abrupt discontinuation of Pralex is officially associated with the emergence of withdrawal symptoms, a condition known as Discontinuation Syndrome. These symptoms may include dizziness, nausea, and sensory disturbances. The official protocol is to reduce the dose gradually (tapering) rather than stopping suddenly.

Q: Does Pralex affect hormones?

A: While regulatory documents do not provide a general statement on all hormones, they explicitly document sexual dysfunction as a common adverse reaction. This includes effects like decreased libido (sex drive) and ejaculation disorder, which are processes often linked to neuroendocrine pathways.

Q: Is it normal to feel a bit worse when first starting Pralex?

A: Official regulatory documents include a Boxed Warning that notes an increased risk of suicidal ideation and behavior in adolescents and young adults during the initial treatment phase or following dose adjustments. Patients should be observed closely during these times, as this indicates a potential worsening of symptoms.

Q: Can Pralex interact with over-the-counter cold and flu medicines?

A: Regulatory warnings exist concerning co-use with other serotonergic agents that affect serotonin levels. Some over-the-counter cold and flu medicines contain ingredients, such as dextromethorphan, that are also serotonergic and could potentially increase the risk of Serotonin Syndrome.

Q: Are there different strengths of Pralex tablets available?

A: The official product labeling confirms that Pralex tablets are available in multiple standard strengths. These typically include 5 mg, 10 mg, and 20 mg doses. A liquid oral solution is also available.

Q: What should I know about Pralex if I drive a car?

A: Official labeling warns that Pralex may cause side effects like drowsiness (somnolence) or dizziness. It may also affect a person’s judgment, thinking, and motor skills, which could potentially impair the ability to operate machinery or drive a car.

Q: Does Pralex have a risk of dependence or addiction?

A: Pralex is not officially classified as a controlled substance and is not associated with the compulsive drug-seeking behavior typical of addiction. However, regulatory documents do note that abrupt cessation can lead to a state of physical dependence, evidenced by symptoms of Discontinuation Syndrome.

Q: Is Pralex known to affect body weight?

A: Regulatory documents note that effects on body weight have been reported during clinical trials. Official labeling lists both weight gain and anorexia (decreased appetite, which can lead to weight loss) as possible adverse reactions.

Q: What should be done if a scheduled dose of Pralex is forgotten?

A: Official patient instructions generally describe a process for handling missed doses, such as taking a forgotten dose the same day it is remembered, or skipping the missed dose entirely if it is already the next day. It is officially advised not to take a double dose to make up for the forgotten one.

Q: Why do some people say Pralex made them feel 'numb'?

A: Official studies and associated literature have examined the possibility of effects on emotional processing. Some research indicates that Pralex may reduce sensitivity to both positive and negative emotional signals, an effect that has been associated with the user-reported experience of emotional blunting or feeling 'numb.'

How should Pralex be stored and disposed of?

How to Store and Dispose of Pralex (Escitalopram)

Official regulatory documents define specific conditions for the storage and disposal of Pralex to ensure product quality and public safety.


Storage Requirements

Pralex must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), and must not be frozen. The medication requires protection from excessive moisture and direct light, and must be kept in a closed container. For safety, it is a mandatory rule to store Pralex out of the sight and reach of children.


Disposal Instructions

Disposal of unused or expired Pralex should primarily utilize an authorized drug take-back program. If a program is unavailable, the medicine must be removed from its container, mixed with an unappealing substance, placed in a sealed bag, and discarded in the household trash. Pralex is not recommended for disposal by flushing down the toilet or pouring down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pralex found in:

A-Z Index: